阴道黄体酮与肌内注射17α-羟孕酮己酸酯预防单胎妊娠复发性早产的比较:系统综述与Meta分析
本系统综述与Meta分析纳入7项随机对照试验共1910例有自发性早产史的单胎妊娠孕妇,比较阴道黄体酮与肌内注射17α-羟孕酮己酸酯的预防效果。阴道黄体酮组早产<34周、<37周、<32周及早产相关药物不良反应和围产期死亡率均低于17α-羟孕酮己酸酯组,但<28周早产无显著差异。在低偏倚风险试验的敏感性分析中,<34周早产差异不再有统计学显著性。
要点
- 阴道黄体酮组早产<34周发生率14.7% vs 19.9%,RR 0.74(95%CI 0.57-0.96)。
- 阴道黄体酮组药物不良反应15.6% vs 22.2%,RR 0.71(95%CI 0.54-0.92)。
- 低偏倚风险试验敏感性分析中<34周早产差异无统计学显著性(RR 0.87,95%CI 0.57-1.32)。
核心结论
- 总体而言,在预防有自发性早产史的单胎妊娠<34周早产方面,阴道黄体酮优于肌内注射17α-羟孕酮己酸酯。
- 尽管高质量研究的敏感性分析显示相同趋势,但差异不再有统计学显著性。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Ovid、Scopus、ClinicalTrials.gov、PROSPERO、SciELO、Embase和Cochrane Central Register of Controlled Trials(CENTRAL)自建库至2021年9月,无语言或地域限制。
- 纳入标准为无症状单胎妊娠且有既往自发性早产史的随机对照试验,干预组为阴道黄体酮,对照组为肌内注射17α-羟孕酮己酸酯。
- 共纳入7项随机对照试验,1910例患者。
- 对低偏倚风险研究和方案注册研究进行事后敏感性分析。
主要发现
- 阴道黄体酮组与17α-羟孕酮己酸酯组相比,<34周早产率14.7% vs 19.9%(RR 0.74,95%CI 0.57-0.96)。
- <37周早产率36.0% vs 46.6%(RR 0.76,95%CI 0.69-0.85)。
- <32周早产率7.9% vs 13.6%(RR 0.58,95%CI 0.39-0.86)。
- <28周早产率两组无显著差异。
- 药物不良反应阴道黄体酮组15.6% vs 17α-羟孕酮己酸酯组22.2%(RR 0.71,95%CI 0.54-0.92)。
关键数值与推荐
- 在至少4项Cochrane工具评为低偏倚风险的试验敏感性分析中,纳入4项试验(N=575),阴道黄体酮组与17α-羟孕酮己酸酯组<34周早产率12.2% vs 13.9%(RR 0.87,95%CI 0.57-1.32),差异无统计学显著性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 在低偏倚风险试验的敏感性分析中,<34周早产差异不再有统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized trials have found benefits of both vaginal progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of recurrent preterm birth. A previous meta-analysis directly comparing the two was limited by low-quality evidence, and national and international society guidelines remain conflicting regarding progestin formulation recommended for prevention of recurrent preterm birth. The aim of this updated systematic review with meta-analysis was to evaluate the efficacy of vaginal progesterone compared with 17-alpha-hydroxyprogesterone caproate in the prevention of spontaneous preterm birth in patients with singleton gestations and previous spontaneous preterm birth. DATA SOURCES: Searches were performed in MEDLINE, Ovid, Scopus, ClinicalTrials.gov, the International Prospective Register of Systematic Reviews (PROSPERO), SciELO, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) with the use of a combination of keywords and text words related to "preterm birth," "preterm delivery," "singleton," "cervical length," "progesterone," "progestogens," "vaginal," "17-alpha-hydroxy-progesterone caproate," and "intramuscular" from inception of each database to September 2021. No restrictions for language or geographic location were applied. STUDY ELIGIBILITY CRITERIA: We included all randomized controlled trials of asymptomatic singleton gestations with previous spontaneous preterm birth that were randomized to prophylactic treatment with either vaginal progesterone (ie, intervention group) or intramuscular 17-alpha-hydroxyprogesterone caproate (ie, comparison group). Post hoc sensitivity analysis was performed for studies with low risk of bias and studies with protocol registration. METHODS: The primary outcome was preterm birth <34 weeks' gestation. The summary measures were reported as relative risks with 95% confidence intervals. RESULTS: Seven randomized controlled trials including 1910 patients were included in the meta-analysis. Patients who received vaginal progesterone had a significantly lower rate of preterm birth at <34 weeks (14.7% vs 19.9%; relative risk, 0.74; 95% confidence interval, 0.57-0.96), preterm birth at <37 weeks (36.0% vs 46.6%; relative risk, 0.76; 95% confidence interval, 0.69-0.85), and preterm birth at <32 weeks of gestation (7.9% vs 13.6%; relative risk, 0.58; 95% confidence interval, 0.39-0.86), compared with women who received intramuscular 17-alpha-hydroxyprogesterone caproate. There were no significant differences in the rate of preterm birth at <28 weeks' gestation. Adverse drug reactions were significantly lower in the vaginal progesterone group than in the 17-alpha-hydroxyprogesterone caproate group (15.6% vs 22.2%; relative risk, 0.71; 95% confidence interval, 0.54-0.92). Perinatal mortality was lower in the vaginal progesterone group than in the 17-alpha-hydroxyprogesterone caproate group (2.2% vs 4.4%; relative risk, 0.51; 95% confidence interval, 0.25-1.01). In sensitivity analysis including trials rated with at least 4 Cochrane tools as of "low risk of bias," 4 trials were included (N=575), and there was no longer a significant difference in preterm birth at <34 weeks' gestation between vaginal progesterone and 17-alpha-hydroxyprogesterone caproate (12.2% vs 13.9%; relative risk, 0.87; 95% confidence interval, 0.57-1.32). CONCLUSION: Overall, vaginal progesterone was superior to 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth at <34 weeks' gestation in singleton pregnancies with previous spontaneous preterm birth. Although sensitivity analysis of high-fidelity studies showed the same trend, findings were no longer statistically significant.
引用
- Boelig RC, Locci M, Saccone G, et al. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2022. PMID: 35562009. doi:10.1016/j.ajogmf.2022.100658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。